Top Contrarian Stocks
Health Care: Drugs
Bristol-Myers Squibb Company (BMY: NYSE)
$26.58 0.15 | 0.57%
09/03/10 - 04:01 PM ET
6.65M / 13.46M
Vol / Avg. Vol:26.46 / 26.43
Open / Prev. Close:26.38 - 26.62
Today's Range:21.67 - 27.07
52 Wk Range:5.27%
Performance YTD:TheStreet Rating:
Portfolios with BMY
- Portfolio NameUser Type
- ContributorCramer's Buyable Opportunites
- ContributorRocket Stocks for the Week ...
- ContributorFast Money's Defensive Stoc...
- ContributorCramer's Wrong Hideout Stocks
- ContributorCramer's Must-Sell Health C...
- ContributorDividend Stocks for the Wee...
- ContributorBarron's Better Than Bonds ...
- ContributorCramer's Bernanke Stock Buys
- ContributorRocket Stocks for the Week ...
- ContributorCramer's Cancer-Fighting St...
Latest BMY Headlines from TheStreet
- More Hostile Biotech, Pharma Deals
09.03.10 | 10:09 am - SunTrust Banks: Upgrades, Downgrades 08.31.10 | 09:08 am
- 21 Drugs Facing FDA Approval Decisions 08.31.10 | 08:08 am
- Pfizer - Upgrades & Downgrades 08.26.10 | 11:08 am
- 10 Alzheimer's Disease Treatment Stocks 08.18.10 | 06:08 am
- Stocks Under $5: Two Finds 08.01.10 | 03:08 pm
- Stocks Under $5: Two New Finds 07.29.10 | 06:07 am
- Biotech ETFs Rise on M&A Buzz 07.26.10 | 11:07 am
- Bristol-Myers Squibb Q2 2010 Earnings Call Transcript 07.22.10 | 07:07 pm
- Business Events Scheduled For Thursday 07.21.10 | 01:07 pm
Press Releases for BMY
- Bristol-Myers Squibb And Pfizer Inc Evaluate Unmet Need In Patients With Atrial Fibrillation - Business Wire 08.25.10 | 08:08 am
- Ipilimumab Receives FDA Priority Review Designation For Adult Patients With Previously Treated Advanced Melanoma - Business Wire 08.18.10 | 01:08 pm
- Data On Investigational Drug Belatacept In Kidney Transplant Recipients To Be Presented At 23rd International Congress Of The Transplantation Society - Business Wire 08.14.10 | 09:08 am
- Bristol-Myers Squibb And ADAP Crisis Task Force Announce Enhanced, Multi-year Support For AIDS Drug Assistance Programs (ADAPs) In The United States - Business Wire 08.11.10 | 10:08 am
- Bristol-Myers Squibb National Survey Finds A Disparity Between Health Care Providers And HIV Positive Patients Perspectives On The Emotional Barriers To Seeking HIV Care And Treatment - Business Wire 07.22.10 | 12:07 pm
- Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data And Double-Digit EPS Growth - Business Wire 07.22.10 | 07:07 am
- Bristol-Myers Squibb To Announce Results For Second Quarter 2010 On July 22 - Business Wire 07.13.10 | 12:07 pm
- SPRYCEL® (dasatinib) Receives FDA Priority Review For The Treatment Of Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) In Chronic Phase - Business Wire 07.09.10 | 05:07 pm
- Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control In Patients With Type 2 Diabetes Inadequately Controlled With Insulin - Business Wire 06.26.10 | 02:06 pm
- 52-Week Study Finds ONGLYZA™ (saxagliptin) When Added To Metformin Was Non-Inferior To Titrated Glipizide When Added To Metformin In Reducing Glycosylated Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus - Business Wire 06.26.10 | 10:06 am
Partner Headlines for BMY
- Week Ahead: It's the Jobs, Silly - Fox Business 08.27.10 | 04:08 pm
- ZGEN's HCV Candidate Progresses - Analyst Blog - Zacks 08.27.10 | 09:08 am
- African police seize 10 tonnes of fake medicines - Reuters 08.26.10 | 10:08 am
- Challenges ahead for Sanofi chief - Financial Times 08.23.10 | 07:08 pm
- Generic Risk For Gilead's Hepsera - Analyst Blog - Zacks 08.20.10 | 02:08 pm
- Good News for BMY Pipeline - Analyst Blog - Zacks 08.19.10 | 04:08 pm
- Drugmakers face scrutiny over payments - Financial Times 08.13.10 | 02:08 am
- Bristol-Myers Has PT Raised By Jefferies Int'l - Benzinga 08.12.10 | 09:08 am
- Legal Briefing: More Cases Under the Foreign Corrupt Practices Act - Daily Finance 08.09.10 | 03:08 pm
- Analyst Stock Picks With Liquidity, Growth and Yield - With Macro Caution - Seeking Alpha 08.02.10 | 06:08 am
